Recurrent diffuse intrinsic brain stem glioblastoma multiforme carries an extremely poor prognosis and a median survival of less than 7 months. In this article, the authors report good results in a 40-year-old man diagnosed with glioblastoma multiforme who received antineoplastons. The patient's brain tumor was diagnosed in May 1999, and he subsequently underwent subtotal tumor resection and standard radiation therapy. Magnetic resonance imaging and positron emission tomography scans documented his tumor recurrence. Approximately 2 months after completion of radiation therapy, he was admitted for administration of intravenous antineoplastons A10 and AS2-1 through a subclavian venous catheter by intermittent bolus injections 6 times per day using a portable pump. Administration of antineoplastons A10 and AS2-1 was over 655 consecutive days with the exception of a few short interruptions. The maximum dosage of A10 was 8.15 g/kg/d and AS2-1 0.35 g/ kg/d. Antineoplastons A10 and AS2-1 administration was very well tolerated with only mild reversible side effects. Follow-up magnetic resonance imaging and positron emission tomography scans revealed decrease and eventually disappearance of the tumor. A complete response was documented after approximately 1 year of antineoplastons A10 and AS2-1 administration. More than 4 years later, off antineoplastons A10 and AS2-1, the patient is tumor free, able to carry on normal activities, and works full-time, and his Karnofsky Performance Status increased from 50 to 100. Extensive phase II trials with antineoplastons A10 and AS2-1 in patients with glioblastoma multiforme are nearing completion. These trials may provide more data regarding the efficacy of antineoplastons A10 and AS2-1 in the treatment of glioblastoma multiforme in untreated patients compared to the results in those patients with tumor recurrence after radiation therapy. like to describe the details of the clinical course of 1 of these patients who has had a complete response to ANP and has survived for more than 4 years.
The conventional treatment of recurrent glioblastoma multiforme (GBM) is disappointing. Curative therapies do not exist, and median survival is approximately 4 months for untreated patients with only a moderate gain in survival with the newest forms of chemotherapy. 1 The treatment is even more challenging for a brain stem location of the tumor. Clearly, treatments based on different principles are needed. Among the most exciting possibilities are agents that work as molecular switches; that is, they "turn on" tumor suppressor genes and "turn off" oncogenes. Recently, a complete response in a patient who had recurrent malignant glioma treated with one of these agents, sodium phenylbutyrate (PB), has been described. 2 PB is almost completely metabolized in the liver into phenylacetate (PN) and phenylglutaminate (PG), which are the active ingredients of antineoplaston (ANP) AS2-1 (AS2-1). 3 Another formulation of antineoplaston A10 (A10) contains phenylacetylisoglutaminate (isoPG) in addition to PG. 4 A preliminary report on a phase II study of ANP in patients with recurrent diffuse intrinsic brain stem gliomas has recently been published. 5 In a small group of 12 patients, there were 5 patients with objective responses (complete and partial responses), 3 patients with stable disease, and 2 patients with progressive disease who subsequently died. Two patients have been surviving for more than 7 years post diagnosis. Another group of patients with a median Karnofsky Performance Status (KPS) of 40 received ANP under a special exception (due to patients' low KPS). 5 In this report, we would
Case Report
The patient is a 40-year-old Caucasian man who was evaluated in Singapore in May of 1999 after he developed progressive numbness of the left forehead, dryness of the left eye, facial weakness, and numbness of the right upper and lower extremities. Magnetic resonance imaging (MRI) of the head showed a mass involving the pons and brachium pontis with an area of contrast enhancement. The enhancing characteristics changed over a period of 10 days, with decreased enhancement on the patient's MRI of the head performed on June 1, 1999, at M. D. Anderson Cancer Center (MDA) in Houston, Texas, just after he returned to the United States. The patient was further evaluated and underwent a left suboccipital craniotomy with subtotal resection of the pontine tumor at MDA on June 2, 1999, per Raymond Sawaya, MD, chairman of the Department of Neurosurgery. The pathological diagnosis was GBM per MDA's neuropathologist, Janet M. Bruner, MD (which was also reviewed by Raymond Sawaya, MD). After the surgery, the patient had some increased left-sided numbness of the face, intermittent diplopia, left facial nerve paralysis, and imbalance. Postoperative MRI of the head revealed residual tumor and postoperative changes ( Figure 1 ). Between June 18, 1999, and August 2, 1999, he underwent radiation therapy at MDA and received 5400 cGy in 30 fractions. Follow-up MRIs of the head of August 23, 1999, and September 22, 1999 (51 days after completion of radiation therapy), confirmed tumor recurrence. Treating physicians at MDA informed the patient that his tumor could not be cured and he may have no longer than 6 months to live, with or without chemotherapy.
On September 30, 1999, 8½ weeks after completion of his radiation therapy, the patient was admitted for administration of ANP based on a special exception to protocol BT-11. 5 At that time, he was found to have right hemiparesis, walking and balance difficulties, vertigo, diplopia, left facial nerve paralysis, a visual field deficit in the left upper quadrant of the left eye, hearing distortion in the left ear, slurred speech, shortness of breath, and indigestion. He required considerable assistance and frequent medical care, and his KPS was determined to be 50. The patient signed the consent form, which was reviewed by the Food and Drug Administration (FDA) and approved by the institutional review board (IRB). The treatment was supervised by the IRB, the membership of which was in agreement with the FDA. The administration of ANP and assessment of safety and efficacy of ANP was previously described. 5 Both formulations of ANP were administered intravenously through a Broviac subclavian venous catheter in gradually escalating doses by intermittent bolus injections (6 times a day) using a portable Provider 6000 dual channel pump (Abbott Laboratories, North Chicago, Ill, USA). The dosage of antineoplaston A10 was gradually increased to 8.15 g/kg/d and AS2-1 to 0.35 g/kg/d. The patient received 655 days of total treatment. After the initial 54 days, the dosage of A10 was decreased to an average of 5.29 g/kg/d and AS2-1 to 0.25 g/kg/d. On several occasions, ANP was discontinued from 1 to 3 days due to mild hypernatremia (from 148 mEq/L to 151 mEq/L). The patient was also off ANP for 2 days due to increased fatigue. On March 29, 2000, his white blood cell count (WBC) decreased to 2.5 × 10 3 /mm 3 ; therefore, he discontinued ANP and was given filgrastim 0.3 mg subcutaneously (SC) daily for 3 days. At that time, his WBC rose to 6.6 × 10 3 /mm 3 , and ANP was restarted. On June 30, 2000, his hemoglobin decreased to 9.0 g/dL, and he was given epoetin alfa 10,000 units SC every other day Figure 1 Glioblastoma multiforme of the brain stem in a 40-yearold man that recurred after partial resection and radiation therapy. T2-weighted (left row) and T1-weighted gadolinium-enhanced (right row) magnetic resonance images of the head. Images in the upper row show the tumor before partial resection, and images in the lower row were performed after partial resection, but prior to radiation therapy.
for 10 days. On July 10, 2000, the WBC decreased to 2.6 × 10 3 /mm 3 . ANP was again discontinued, and the patient received filgrastim 0.3 mg SC daily for 3 days. Follow-up MRIs of the head at 8-week intervals showed a continuous decrease of the size of the tumor. Figures 2 and 3 show the initial and follow-up MRIs of the head after 4 months and 3 years, respectively, and document marked decrease of the tumor size. The patient's response was also followed by repeat positron emission tomography (PET) scan to determine the viability of the tumor and confirm the response. On December 20, 2000, the patient's results were classified as complete response based on the PET, which showed no hypermetabolic lesions. Figure 4 shows PET of the brain initially and after approximately 15 months of ANP administration and confirms the disappearance of the hypermetabolic lesion. (MRI and PET scans were performed and reviewed at MDA.) The most recent clinical evaluation of December 1, 2003, showed the patient in good condition and complaining only of minor symptoms including slight balance difficulties, decreased lacrimation in the left eye, left-sided facial muscle weakness, and slight shortterm memory deficit. The patient is able to carry on normal activities and works full-time (KPS = 100). The most recent MRI of the head of November 26, 2003, did not reveal tumor recurrence.
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Discussion
Active ingredients of A10 and AS2-1 (PN and PG) have been tested separately in clinical trials; however, they have either failed or showed only some activity in patients with recurrent malignant gliomas. [5] [6] [7] [8] A phase I study of PB in 22 patients provided more optimistic re-sults, with 1 case of a complete response and 4 cases of stable disease. 9 Combination treatment with A10 and AS2-1 (active ingredients PG, isoPG, and PN) provided better results than with A10 or AS2-1 individually. 4, 5, 10, 11 Buckner et al obtained no response to A10 and AS2-1 in their limited study, which involved only 6 evaluable patients (most of them with GBM). 12 Three phase II studies confirmed the necessity of extended administration of high doses of A10 and revealed 30%, 44%, and 50% objective responses (complete and partial responses). 5, 10, 11 The main difference between Buckner et al's study and these studies is the dosage of A10, which was approximately 50 times lower in Buckner et al's study, whereas the average maximum dosage of AS2-1 was the same. 13 An important issue for discussion is the possible contribution of radiation therapy to the long-term control of the disease. In this patient, radiation therapy was completed more than 8 weeks before beginning ANP, and its failure was confirmed by tumor recurrence on MRI of the head performed 51 days after completion of radiation. Also, follow-up PET, performed 14 weeks after completion of radiation, continued to show an active hypermetabolic tumor (Figure 4) .
It is not unusual to accept patients to a phase II study 8 weeks post radiation therapy, such as in a recent phase II study of recurrent GBM conducted in the 10 leading brain tumor treatment centers, in which the patients were admitted at least 4 weeks post radiation therapy. In one study, the median survival for intravenous carboplatin with blood-brain barrier disruption was 6½ months. 1 It is unlikely that radiation therapy alone is the cause of long-term survival in this patient; however, we cannot exclude the possibility of the synergistic effects of radiation therapy followed by ANP. Phase II studies of 2 groups of patients with GBM are currently nearing completion comparing results of patients receiving ANP after radiation therapy failure to patients receiving ANP without prior radiation therapy, which may provide the answer to the above question. This case report may also have important consequences because it describes the successful treatment of a highly aggressive malignant tumor with a poor prognostic location in the brain stem.
The mechanism of action of ANP is believed to occur on a molecular level, affecting the genes involved in the formation of brain tumors by decreasing expression of the oncogenes AKT2, RAS, and MYCC and activating the tumor suppressors TP53, p21, PTEN, and INI1. 4, 5, 14, 15 The 3 active ingredients that constitute 
